Search

everythinglearnresearchcommunity

for

Search:↓

Men taking 5-alpha reductase inhibitors for prostate issues may be less likely to experience severe COVID-19, but it doesn't prevent ICU admission or death.

PrEP doesn't increase STI risk in high-risk men, anti-androgen drugs may lower ICU admission for male COVID-19 patients, a 3-point injection is better for crow's feet, and the 'Geriatric-8' tool could help assess frailty in older skin cancer patients.

Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.

Older males had higher death rates, and Latin Americans were more often in the ICU during the COVID-19 outbreak in a Spanish hospital.

Most COVID-19 survivors developed post-acute symptoms, especially if they had been in the ICU, but the severity of initial infection didn't predict these symptoms.

Some COVID-19 patients have skin issues, with men, ICU patients, and those on multiple antibiotics at higher death risk; in-person skin checks by dermatologists are more effective.

Survivors of severe COVID-19 need ongoing care to manage lasting health issues.

Non-Kuwaiti COVID-19 patients had worse health outcomes than Kuwaitis, likely due to poorer socioeconomic conditions.

Many COVID-19 survivors experience long-term symptoms but still report satisfactory quality of life and return to work.

Patients with chronic skin conditions on systemic treatments did not have worse COVID-19 outcomes and could resume their treatments after recovery.

A certain genetic variant in the androgen receptor may predict the severity of COVID-19 in men.

Men face more severe COVID-19 outcomes, while women are more likely to have long-term symptoms.

Testosterone may have a dual role in COVID-19, potentially worsening outcomes in men, and testosterone therapy could help some patients, but more research is needed.

MIS-A is a severe complication after COVID-19, mostly in young black males, needing more research and awareness.

Most COVID-19 patients had lingering symptoms 60 days after leaving the hospital.

Severe male balding may increase the risk of serious COVID-19, and treatments that reduce androgens or block a specific enzyme might help protect these individuals.

Anti-angiogenic drugs do not worsen COVID-19 severity in lung cancer patients.

About 61% of women who had COVID-19 experienced hair loss afterward.

Recognizing lupus as a cause of severe gut issues is crucial for effective treatment.

Many survivors of critical illness, especially those with sepsis, experience hair loss.

Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.

The meeting discussed medical findings, including benefits of certain treatments for cancer and heart conditions, and highlighted issues like poor adherence to preventive measures and skill gaps among interns.

After severe COVID-19, 71% of patients experienced excessive hair shedding and thinning within 3 months due to factors like low oxygen levels, medication, stress, and autoimmune disease.

Most hospitalized COVID-19 patients had long-term symptoms like fatigue and hair loss, with women and those sicker during hospitalization at higher risk.

Sex hormones likely did not affect COVID-19 outcomes in South Korea.

A woman with asthma improved from a severe fungal infection after treatment change, and most HIV-positive women in a UK study had low immune cell counts but were responding well to treatment.

Men are more likely to have severe COVID-19 cases and fatalities than women due to factors like lifestyle, aging, and biological differences.

A woman had severe reactions to methotrexate, including skin issues and organ problems, but improved after 38 days in the hospital.

Ingesting minoxidil can cause serious heart problems and requires urgent medical treatment.

Different drugs are linked to specific mental health issues.